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Abstract: 
The objective of this study was to assess the prevalence of multi-drug resistance isolates of Klebsiella pneumoniae among the 
patients at Northern Area Armed Forces Hospital (NAAFH) of the Eastern region of Saudi Arabia. This retrospective, chart 
review observational study was conducted from February 1, 2016 to February 29, 2016 at Northern Area Armed Forces Hospital 
(NAAFH), a 330-bed community  general hospital located in the Eastern region of Saudi Arabia. A total of 870 isolates were 
identified in 298 patients (3 isolates per patient involving multiple sites). It was observed that the risk of females being infected or 
colonized with K. pneumoniae was higher than males; the K. pneumoniae was more frequently encountered in hospitalized 
patient compared to outpatients; a greater number of isolates were obtained from medical service; and the K. pneumoniae was 
more likely to be isolated from the genitourinary system. Prevalence of multi-drug resistance of K. pneumoniae to antibacterial 
agents showed that 41% isolates were resistant to third generation cephalosporin primarily due to production of ESBLs, but this 
was considered statistically insignificant (RR 1.18; 95% CI, 0.96 to 1.47; p = 0.131). The K. pneumoniae producing 
carbapenemase (KPC) were significantly prominent in this series (RR 0.32; 95%CI, 0.23 to 0.43; p < 0.001). The rapid growth 
of the K. pneumoniae species that are resistant to carbapenem, a class of drugs considered the last-line of defense, is a matter of 
concern. 
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INTRODUCTION: 
Infections caused by Klebsiella pneumoniae have 
become endemic in health care systems [1]. This 
organism can be found as normal flora in the mouth, 
skin, and intestinal tract, where it initially does not 
cause disease [2]. Although found in these organ 
systems as normal flora, K. pneumoniae can progress 
into severe bacterial infections leading to pneumonia, 
bloodstream infections, wound infections, urinary 
tract infections, and meningitis. Patients who require 
equipment such as catheters or ventilators are at high 
risk for infections. Also, a patient administered a 
course of broad-spectrum antibiotic treatment is at an 
even higher risk due to the disruption of the normal 
flora of the bacteria in the body, deeming it more 
susceptible to pathogens [2]. The principal 
pathogenic reservoirs for transmission of Klebsiella 
are the gastrointestinal tract and the hands of hospital 
personnel. Because of their ability to spread rapidly 
in the hospital environment, these bacteria tend to 
cause nosocomial outbreaks [3]. Hospital outbreaks 
of multidrug-resistant Klebsiella spp., especially 
those in neonatal wards, are often caused by new 
types of strains, the so-called extended-spectrum-
beta-lactamase (ESBL) producers [4]. What is of 
major concern clinically is the current onslaught of 
multi-drug resistant K. pneumoniae species that have 
also become resistant to carbapenems [1, 3-6]. 
Reports from elsewhere highlight the challenges 
faced by infectious disease specialists and healthcare 
systems management of treating these isolates owing 
to the limited formulary antibacterial armament [1-6]. 
To the best of our knowledge studies related to the 
assessment of the prevalence of multi-drug resistance 
isolates of Klebsiella pneumoniae among the patients 
in some regions of Saudi Arabia has not been carried 
out. Accordingly, the objective of this study was to 
assess the prevalence of multi-drug resistance isolates 
of Klebsiella pneumoniae among the visitor at 
Northern Area Armed Forces Hospital (NAAFH) of 
the Eastern region of Saudi Arabia. 
 
METHODS: 
This retrospective, chart review observational study 
was conducted from February 1, 2016 to February 
29, 2016 at Northern Area Armed Forces Hospital 
(NAAFH), a 330-bed community  general hospital 
located in the Eastern region of Saudi Arabia. The 
hospital has 40 intensive care unit beds (12 adult, 21 
neonatal and 6 pediatric) with approximately 4,716 
admissions per year. In addition, the hospital operates 
about 8 peripheral health care centers (clinics) that 
offer primary care (ambulatory) services to the 
community. The outpatient and central pharmacy are 
located in the hospital proper adjacent to the medical 
laboratory (central pharmacy). Each peripheral clinic  
 
has a pharmacy which is limited to a primary health 
care formulary. 
 
Data Collection  
Data were collected on all patients within NAAFH 
(inpatient and outpatient) in whom K. pneumoniae 
was isolated by the microbiology laboratory. This 
study was approved by Northern Area Armed Forces 
Hospital Ethics Committee (February 16, 2016). 
Clinical patient information was collected from the 
patients’ antibiogram, missing patient data was 
accessed through the computerized physician order 
entry (CPOE) by the investigator. Data collected 
included demographic information, patient location, 
type of service or sub-specialty where applicable, 
anatomical site of the isolate. Patients treated with at 
least one of the following were analyzed; cefazolin, 
cefuroxime, ceftriaxone, cefotaxime, ceftazidime, 
imipenem-cilastatin, piperacillin-tazobactam, 
ciprofloxacin, levofloxacin, cefepime, amikacin, 
gentamicin, tobramycin and 
trimethoprim/sulfamethoxazole (TMP/SMX) in 
whom K. pneumoniae was confirmed using the CDC 
definitions [7] for infection. The initial K. 
pneumoniae isolate was considered the baseline 
isolate. Baseline resistance was defined as resistance 
of baseline isolate to any of the study antibacterials 
and multi-drug resistance was defined as resistance to 
any 3 of these antibacterials. Microbiologic outcomes 
were categorized as “susceptible”, “baseline 
resistance”, “multi-drug resistant”, “extended-
spectrum beta-lactamases (ESBL) producers” and 
“carbapenem-resistance enterobacteriaceae (CRE)”. 
These outcomes were compared between services, 
between community-acquired versus hospital-
acquired (nosocomial) infection. 
 
The minimal inhibitory concentrations used to 
determine susceptibility thresholds for the different 
antibacterials aimed at K. pneumoniae were, 
according to the NAAFH guidelines (≤ 8 for 
cefazolin, ≤ 4 for cefuroxime ≤ 8 µg/mL for 
piperacillin-tazobactam, < 8 µg/mL for cefepime, < 1 
µg/mL for ceftazidime, ≤ 4 for ceftriaxone, ≤ 2 for 
cefotaxime, < 4µg/mL for imipenem-cilastatin, ≤ 2 
µg/mL for levofloxacin, ≤ 1µg/mL for ciprofloxacin, 
< 1 for gentamicin, TMP/SMX ≤ 0.5/9.5 and < 2 for 
tobramycin). Isolates with intermediate susceptibility 
were considered resistant. At NAAFH, MICs for 
meropenem and aztreonam are not routinely 
performed. All collected data were entered into an 
Excel® spreadsheet (Microsft Corporation, Redmond. 
Wash.).  
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Data analysis 
Descriptive statistics were used to summarize data. 
Demographic data and all other categorical variables 
were analyzed using the χ2 statistic and Fischer’s 
exact test between genders. Continuous variables 
such as age were analyzed using Student t-test or 
Mann-Whitney U-test for nonparametric data. 
Comparisons between the frequency of isolating K. 
pneumoniae in hospitalized patients (nosocomial) 
versus isolates from the community as well as the 
frequency of susceptible isolates compared to 
resistant ones were quantified using the relative risk. 
Multivariate regression was performed to establish 
correlations between variables and the Pearson’s 
product-moment correlation coefficient (r2) was used. 
Alternatively, either Kendall’s tau correlation or 
Spearman rho correlation was used for ordinal 
variables where applicable. Multiple regression 
statistics were employed in the case of multiple 
variances. Data were analyzed using Stata (Version 
12; StataCorp, College Station, TX, USA) statistical 
software. Statistical significance was defined with a p 
value of less than 0.05.  
 
RESULTS:  
A total of 870 isolates of K. pneumoniae were 
recovered from 298 patients (average of 2.9 isolates 
per patient from multiple sites). The overall average 
age of our study population was 50.39±28.07. 
Females, on average, were significantly younger than 
their male counterparts (46.08 ± 28.23 vs 57.76 ± 
27.47; 95%CI, -18.23 to -5.1; p = 0.0006). Females 
were significantly more likely to be infected or 
colonized with K. pneumoniae than males (63% vs 
37%; 95% CI, 0.576 to 0.686). The distribution of K. 
pneumoniae by age range indicates that most of the 
isolates were recovered from the 71-80 age range 
(22%, 66). The 31-40 age range was next with 45 
isolates (15%) followed by the 21-30 (13%), 0-10 
(12%) and the 41-50 (10%) age ranges. In the 51-60 
(8%), 61-70 (6%) age ranges, K. pneumoniae was not 
as common as the foregoing age ranges. K. 
pneumoniae was isolated with less frequency in the 
81-90 (6%), 91-100 (3%) and in the age range greater 
than 100 (4%) (Figure 1). 
 
K. pneumoniae was more frequently encountered in 
hospitalized patients (nosocomial) compared to 
patients visiting outpatient clinics (80% vs 20%; 95% 
CI, 0.156 to 0.247). Of the patients who acquired K. 
pneumoniae from the hospital (nosocomial), a greater 
number were isolated from the medical service (44%) 
followed very closely by intensive care units (41%) 
[adult intensive care unit (ICU) 74%, pediatric (ICU) 
19% and neonatal (ICU) 7%] (Figure 2). The K. 
pneumoniae was more likely to be isolated from the 
genitourinary system (46%) followed by the 
respiratory (25%), others (25%), and wound (18%) 
and less frequently encountered were K. pneumoniae 
isolated from the bloodstream (4%). These findings 
were found to be statistically insignificant (p = 
0.878). 
 
Prevalence of multi-drug resistance of K. pneumoniae 
(Table 1) to anti-bacterial showed that 41% isolates 
were resistant to third generation cephalosporin 
primarily due to production of ESBLs, but this was 
considered statistically insignificant (RR 1.18; 95% 
CI, 0.96 to 1.47; p = 0.131). However, resistance of 
K. pneumoniae to cephalosporin as a class (including 
1st and 2nd generation cephaolosporin) was 
statistically significant (RR = 1.27; 95% CI, 1.14 
to1.41; p < 0.001). The Klebsiella pneumoniae 
producing carbapenemase (KPC) were significantly 
prominent in this series (RR 0.32; 95% CI, 0.23 to 
0.43; p < 0.001). All other resistance patterns of K. 
pneumoniae to formulary antibacterial were 
statistically non-significant. 
 
DISCUSSION:  
The prevalence of multi-drug resistant K. 
pneumoniae due to ESBL production was identified 
in 121 (41%) patients in this study. ESBL producing 
K. pneumoniae poses a unique challenge in the 
treatment and eradication of this organism given 
limited formulary options available. Currently, to 
treat ESBL-producing K. pneumoniae clinicians have 
to use carbapenem. Carbapenem are stable in the 
presence of hydrolytic effects of ESBLs, which may 
explain the consistent finding that 98% of ESBL-
producing organisms retain susceptibility to either 
imipenem or meropenem [11-13]. These reports are 
consistent with our findings in that in the current 
study, all ESBL-producing isolates were susceptible 
to imipenem or meropenem, but 38% were resistant 
to piperacillin-tazobactam, 31% were resistant to 
aminoglycosides, and 37% were resistant to 
ciprofloxacin (Figure 2). Other reports have 
suggested that the inferior outcome associated with 
apparently active cephalosporin and β-lactam / β-
lactamase inhibitors, compared with that for other 
antibiotic classes, could be explained by the 
inoculum effect [14]. This effect (in which MICs of a 
drug increase up to 100-fold in the presence of 
increased inocula) is consistently observed with 
cefotaxime, ceftriaxone, and cefepime against ESBL-
producing organisms [14]. An inoculum effect is 
least frequently observed with carbapenem; 
piperacillin-tazobactam has an inoculum effect 
intermediate between those of carbapenem and 
cephalosporin [14]. Apart from the inoculum effect, 
an alternative explanation for failure of β-lactam 
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antibiotics is failure to achieve pharmacodynamic 
targets. Quinolones are not prone to substantially 
increase their MICs against ESBL-producing strains 
as the inoculum increases. The relatively poor 
outcome for patients treated with quinolones in this 
study is possibly the result of under dosing [15]. 
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Fig 1: Prevalence of K. pneumoniae by age range 
Table 1: Demographic, clinical and microbiological data 
 
 Parameter  
Nosocomial 
(N = 238) 
Community
-acquired 
(N = 60) RR 95% CI p-Value 
Age  55.3 ±  29.1 31.1 ±  13.7 – -29 to -19 <0.001 
Female, n (%) 141 (75%) 47 (25%) 0.76 0.64 to 0.90 = 0.005 
Site of isolation 
Blood, n (%) 12(4%) 0    
Genitourinary, n (%) 93 (39%) 43 (72%) 0.55 0.44 to 0.68 = 
0.000006 
Respiratory, n (%) 74(31%) 0 – – – 
Skin and skin structure infection, n (%) 43(18%) 10 (17%) 1.08 0.58 to 2.03 = 0.82 
Other*, n (%) 16(7%) 7 (12%) 0.58 0.25 to 1.34 = 0.22 
Intensity of culturing (susceptibility patterns) 
Antibiotic Class 
Susceptible 
 N, (%)  
Resistant N, 
(%) RR 95% CI p-Value 
Cephalosporin, n (%) 516 (58) 378 (42) 1.27 1.14 to1.41 0.001 
1st  generation 168 (56.38) 130 (43.62) 1.34 1.09 to 1.66 0.008 
2nd generation 171 (57.38) 127 (42.62) 1.28 1.04 to 1.60 0.023 
3rd generation 177 (59.40)  121 (40.60) 
(ESBLs) 
1.18 0.96 to 1.47 0.131 
Aminoglycoside, n (%) 194 (65.10) 104 (34.90) 0.93 0.74 to 1.16 0.507 
Quinilone, n (%) 189 (63.42) 109 (36.58) 0.10 0.80 to 1.24 0.984 
Carbapenem, n (%) 252 (84.56) 46 (15.44) 
(CRE) 
0.32 0.23 to 0.43 <0.001 
Piperacillin/tazobactam, n (%) 184 (61.74) 114 (38.26) 1.07 0.87 to 1.33 0.536 
Sulfamethoxazole/trimethoprim, n (%) 178 (59.73) 120 (40.27) 1.17 0.94 to 1.45 0.167 
RR = relative risk or risk ratio. CI =confidence interval; n = number of patients. 
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Fig 2: Susceptibility of K. pneumoniae to Antibiotic classes 
 
The increase in ESBL-producing Klebsiella 
pneumoniae can be attributable to the extensive use 
of third-generation cephalosporin in this study. 
Reports from elsewhere state that extended 
spectrum β-lactamase enzymes were first described 
in K. pneumonia and Serratia marcescens isolates in 
1983 in Europe [16] and in K. pneumoniae and 
Escherichia coli isolates in 1989 in the United States 
[17]. Since then, there has been a marked increase in 
the incidence of bacteria that produce ESBL 
enzymes. There is strong agreement between the 
ESBL-producing K. pneumoniae data in our report 
compared to other reports elsewhere in that ESBLs  
were recorded at 41% in our report compared to 91% 
in the 2006-2011 surveillance report, a 50% increase 
(Figure 2). Our results correlate with findings from 
the United States where the proportion of K. 
pneumoniae strains resistant to ceftazidime increased 
from 1.5% in 1987 to 3.6% in 1991, and by 1993 as 
many as 20% of the strains were resistant to 
ceftazidime in some teaching hospitals [18,19]. Of 
824 K. pneumoniae strains isolated from 15 hospitals 
in New York City during 1999, 34% expressed ESBL 
enzymes [20]. 
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Fig 3: Proportion of 3rd generation use versus ESBL-producing 
 
There was a strong correlation (r2 = 0.79) between 
the proportion of third generation cephalosporin used 
and the production of ESBLs (Figure 3). 
Epidemiological studies suggest that the increasingly 
widespread use of third-generation cephalosporin is a 
major risk factor that has contributed to the 
emergence of ESBL-producing K. pneumoniae [21-
23]. Several additional risk factors for colonization 
and infection with ESBL-producing organisms (not 
included in our report) have been reported and 
include: arterial and central venous catheterization, 
gastrointestinal tract colonization with ESBL-
producing organisms, prolonged length of stay in an 
intensive-care unit, low birth weight in preterm 
infants, prior antibiotic use, and mechanical 
ventilation [20-22]. Furthermore, there is strong 
agreement between our findings and reports from 
elsewhere [23] in that patients in the long-term unit 
(medical service) were identified as mostly affected 
(44%) due to increased length of stay as well as 
patients in the ICU (41%). Carriage of this organism 
increases dramatically among hospitalized patients, 
as colonization rates increase in direct proportion to 
the length of stay [23] (Figure 4). 
 
Outbreaks of ESBL-producing organisms have been 
described. Asymptomatic patients colonized with 
ESBL-producing K. pneumoniae can serve as 
reservoirs for this pathogen with subsequent patient-
to-patient spread via the hands of health care 
workers. In addition, contaminated patient-care items 
and artificial fingernails worn by health care workers 
have been implicated in transmission [24-27]. Most 
studies have demonstrated a poor adherence to 
infection control policies as an important factor. 
Outbreaks of ESBL-producing K. pneumoniae in 
NICUs have been notable for high attack rates and 
large numbers of colonized infants [28]. The 
neonates at greatest risk for colonization are those 
with a longer length of stay, a lower estimated 
gestational age and/or a lower birth weight [23]. 
maternity
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Fig 4: Isolation of nosocomial K. pneumoniae by service 
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Table 2: Relationship between carbapenem utilization and susceptibility 
 
    Year  % susceptible Quantity used 
95%CI (quantity used) 
Lower  Upper  
2007 98 9271 0.0720 0.0773 
2008 99 2634 0.0932 0.0994 
2009 99 3402 0.1384 0.1457 
2010 100 5021 0.1199 0.1268 
2011 100 4358 0.1729 0.1809 
2014 95 6251 0.1214 0.1282 
2015 85 4410 0.2577 0.2669 
 
Prescribing carbapenem due to multi-drug resistance, 
including ESBL production (Table 2) has resulted in 
selection pressure that favors resistance to 
carbapenem through the production of 
carbapenemase [29,30] resulting in “carbapenem-
resistant K. pneumoniae” (CRKP) [29] through 
production of what is known as KPC (Klebsiella 
pneumoniae carbapenemase)-type β-lactamase 
[29,30] which fall under what is currently known as 
carbapenem resistant Enterobacteriaceae (CRE) [31]. 
In this report, there was a weak inverse correlation (r2 
= -0.01123) between carbapenem utilization and the 
emergence of carbapenem resistance (Table 2). When 
comparing K. pneumoniae resistance to carbapenem 
between 2015 (15%) and 2007 – 2011 report (2%), it 
can be seen that there has been an increase in 
resistance no carbapenem by isolates of K. 
pneumoniae [10].   
 
Other reports state that although CRE remain 
relatively uncommon in most acute-care hospitals in 
the United States, they have become an increasingly 
recognized cause of infection during the past decade, 
especially among Klebsiella, likely because of the 
emergence of carbapenemase-producing strains [32, 
33]. In 2012, the number of facilities reporting CRE 
as a cause of infection was small, and spread of these 
organisms appears to be uneven both regionally and 
among facilities within regions. Fewer than 5% of 
short-stay acute-care hospitals reported CRE from 
health-care–associated infections in the first half of 
2012 [32]; CRE more often were reported from 
LTACHs. Data from population-based surveillance 
suggest most CRE clinical isolates came from 
cultures collected outside of hospitals from patients 
with substantial health care exposures [31]. These 
findings suggest that although CRE are increasing in 
prevalence, their distribution is limited [31, 32]. 
 
CRE is important for several reasons. First, invasive 
infections (e.g., bloodstream infections) with CRE 
are associated with mortality rates exceeding 40% 
[31, 33]; this is significantly higher than mortality 
rates observed for carbapenem-susceptible 
Enterobacteriaceae. Of note, because the majority of 
positive cultures were from urine, overall in-hospital 
mortality rates associated with positive cultures were 
lower in the EIP CRE surveillance (4%) [33]. 
Second, carbapenem-resistant strains frequently 
possess additional resistance mechanisms that render 
them resistant to most available antimicrobials; pan-
resistant CRE has been reported [34]. Further, novel 
antimicrobials for multidrug-resistant gram-negative 
bacilli are in early stages of development and not 
likely to be available soon [35]. Third, CRE can 
spread rapidly in health care settings [36, 3]. Fourth, 
Enterobacteriaceae is a common cause of community 
infections, and CRE have the potential to move from 
their current niche among health-care–exposed 
patients into the community [37, 38]. The K. 
pneumoniae was significantly isolated from 
hospitalized patients (80% vs 20%, p < 0.001). 
 
CONCLUSION:  
Resistance of K. pneumoniae to available formulary 
antibiotics is concerning in view of the fact that no 
new antibiotics are in the pipeline. What is of more 
concern to infectious disease specialists and 
healthcare systems is the rapid growth of K. 
pneumoniae species that are resistant to carbapenem, 
a class of drugs considered the last-line of defense. 
Our findings are supported by reports in another 
series of patients as demonstrated above. Our 
findings that 41% of K pneumoniae isolates produced 
ESBLs and that 15% produced KPC are disturbing. 
Reports have indicated that multi-drug resistant 
organisms are associated with increased hospital  
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length of stay and an increase in health care resource 
consumption. It’s prudent that health care systems 
implement strategies that would arrest the spread of 
multi-drug resistant K. pneumoniae. 
 
STUDY LIMITATIONS 
The study design being retrospective poses certain 
challenges in missing patient data. Microbiology 
surveillance data were missing for certain 3 years as 
indicated above. Therefore, the outcomes of our 
findings should be interpreted with caution.  
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